Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Abstract

The global number of patients with diabetes mellitus (DM) has been growing steadily. Over the past decade, the number has more than doubled and reached 371 million people by 2013. [1] In most cases it is type 2 diabetes. The dangerous consequences of DM include micro- and macrovascular complications: nephropathy, retinopathy, lesions of the major blood vessels in the heart, brain and lower limbs. Late complications of DM are a major cause of disability and mortality of the patients.

Keywords

• сахарный диабет
• сахароснижающие препараты
• гликемия
• инкретин
• глюкагоноподобный пептид-1
• випидия
• diabetes mellitus
• hypoglycemic agents
• glycemia
• incretin
• glucagon-like peptide-1
• vipidia